Comparative Pharmacology
Head-to-head clinical analysis: DESLORATADINE versus XYZAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESLORATADINE versus XYZAL.
DESLORATADINE vs XYZAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist selective for the H1 receptor, inhibiting histamine release from mast cells and basophils. It reduces allergic inflammation by decreasing cytokine and chemokine release.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
5 mg orally once daily.
5 mg orally once daily in the evening.
None Documented
None Documented
Terminal half-life 27 hours (range 21–30 h) in healthy adults; supports once-daily dosing.
Clinical Note
moderateDesloratadine + Venlafaxine
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Venlafaxine."
Clinical Note
moderateDesloratadine + Nefazodone
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Nefazodone."
Clinical Note
moderateDesloratadine + Stiripentol
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Stiripentol."
Clinical Note
moderateTerminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Primarily renal (87% as metabolites, ~41% unchanged) and fecal (~9%). Metabolized to active 3-hydroxydesloratadine.
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Category A/B
Category C
Antihistamine
Antihistamine
Desloratadine + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desloratadine."